Galectin reports 68.1% reduction in new varices with belapectin in U.S. patients from NAVIGATE trial

GALECTIN THERAPEUTICS INC

Per-protocol U.S. patients (n=186): 68.1% reduction in new varices with belapectin 2 mg vs placebo (p=0.02).
New prevalence estimate: ~3 million U.S. adults with MASH cirrhosis and clinically significant portal hypertension.
Top-line composite endpoint missed statistical significance in ITT (N=355); completer analysis had 49.3% reduction (p=0.04 revised).
Full analysis ongoing; additional 36-month data expected by end of Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.